{{Drugbox
| IUPAC_name = (6''R'')-4-(2-Chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6''H''-thieno[3,2-''f''][1,2,4]triazolo[4,3-''a''][1,4]diazepine
| image = Israpafant.svg
| width = 265

<!--Clinical data-->
| tradename =  
| legal_US = Investigational New Drug
| legal_status =

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number =  117279-73-9
| PubChem = 636426
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID      = 552203

<!--Chemical data-->
| C=28 | H=29 | Cl=1 | N=4 | S=1
| molecular_weight = 489.074 g/mol
| smiles = C[C@@H]1C2=NN=C(N2C3=C(C=C(S3)CCC4=CC=C(C=C4)CC(C)C)C(=N1)C5=CC=CC=C5Cl)C
| StdInChI = 1S/C28H29ClN4S/c1-17(2)15-21-11-9-20(10-12-21)13-14-22-16-24-26(23-7-5-6-8-25(23)29)30-18(3)27-32-31-19(4)33(27)28(24)34-22/h5-12,16-18H,13-15H2,1-4H3/t18-/m1/s1
| StdInChIKey = RMSWMRJVUJSDGN-GOSISDBHSA-N
}}

'''Israpafant''' ('''Y-24180''')  is a drug which acts as a selective antagonist for the [[platelet-activating factor receptor]],<ref>{{cite journal | last1 = Hirota | first1 = N | last2 = Yasuda | first2 = D | last3 = Hashidate | first3 = T | last4 = Yamamoto | first4 = T | last5 = Yamaguchi | first5 = S | last6 = Nagamune | first6 = T | last7 = Nagase | first7 = T | last8 = Shimizu | first8 = T | last9 = Nakamura | first9 = M | date = Feb 2010 | title = Amino acid residues critical for endoplasmic reticulum export and trafficking of platelet-activating factor receptor | journal = Journal of Biological Chemistry | volume = 285 | issue = 8| pages = 5931–40 | doi = 10.1074/jbc.M109.066282 | pmid = 20007715 | pmc=2820818}}</ref> and was originally developed for the treatment of [[asthma]].<ref>{{cite journal | doi = 10.1164/ajrccm.152.4.7551370 | title=Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. | journal=American Journal of Respiratory and Critical Care Medicine | date=1995 | volume=152 | issue=4 | pages=1198–1202 | first=S | last=Hozawa | pmid=7551370}}</ref> Its chemical structure is a [[thienotriazolodiazepine]], closely related to the sedative [[benzodiazepine]] derivative [[etizolam]]. However israpafant binds far more tightly to the platelet-activating factor receptor, with an IC<sub>50</sub> of 0.84nM for inhibiting PAF-induced human platelet aggregation (compared to etizolam's IC<sub>50</sub> of 998nM at this target), while it binds only weakly to benzodiazepine receptors, with a Ki of 3680nM.<ref>{{cite journal | doi = 10.1016/0090-6980(90)90002-D | title=Pharmacological actions of Y-24180, a new specific antagonist of Platelet Activating Factor (PAF): II. Interactions with PAF and benzodiazepine receptors | journal=Prostaglandins | date=1990 | volume=40 | issue=6 | pages=571–583 | first=S. | last=Takehara}}</ref> Israpafant has been found to inhibit the activation of [[eosinophil]] cells,<ref>{{cite journal | pmid = 10503965 | volume=65 | issue=13 | title=Inhibition of activation of human peripheral blood eosinophils by Y-24180, an antagonist to platelet-activating factor receptor | journal=Life Sci | pages=PL171-6 | last1 = Komatsu | first1 = H | last2 = Amano | first2 = M | last3 = Yamaguchi | first3 = S | last4 = Sugahara | first4 = K | doi=10.1016/s0024-3205(99)00385-9}}</ref><ref>{{cite journal | last1 = Mizuki | first1 = M | last2 = Komatsu | first2 = H | last3 = Akiyama | first3 = Y | last4 = Iwane | first4 = S | last5 = Tsuda | first5 = T | year = 1999 | title = Inhibition of eosinophil activation in bronchoalveolar lavage fluid from atopic asthmatics by Y-24180, an antagonist to platelet-activating factor | url = | journal = Life Sciences | volume = 65 | issue = 20| pages = 2031–9 | pmid = 10579457 | doi=10.1016/s0024-3205(99)00470-1}}</ref><ref>{{cite journal | last1 = Satoh | first1 = T | last2 = Tahara | first2 = E | last3 = Yamada | first3 = T | last4 = Watanabe | first4 = C | last5 = Itoh | first5 = T | last6 = Terasawa | first6 = K | last7 = Nagai | first7 = H | last8 = Saiki | first8 = I | date = Feb 2000 | title = Differential effect of antiallergic drugs on IgE-mediated cutaneous reaction in passively sensitized mice | url = | journal = Pharmacology | volume = 60 | issue = 2| pages = 97–104 | pmid = 10657759 | doi=10.1159/000028353}}</ref> and consequently delays the development of immune responses. It has also been shown to have anti-[[nephrotoxic]] properties,<ref>{{cite journal | last1 = Kawaguchi | first1 = A | last2 = Sugimoto | first2 = K | last3 = Fujimura | first3 = A | date = Jan 2001 | title = Preventive effect of platelet-activating factor antagonist, Y-24180, against cyclosporine-induced acute nephrotoxicity | url = | journal = Life Sciences | volume = 68 | issue = 10| pages = 1181–90 | pmid = 11228102 | doi=10.1016/s0024-3205(00)01028-6}}</ref> and to mobilize calcium transport.<ref>{{cite journal | last1 = Chao | first1 = YY | last2 = Jan | first2 = CR | date = Jan 2004 | title = Effect of Y-24180 on Ca2+ movement and proliferation in renal tubular cells | url = | journal = Life Sciences | volume = 74 | issue = 7| pages = 923–33 | pmid = 14659980 | doi=10.1016/j.lfs.2003.09.033}}</ref>

==See also==
* [[JQ1]]

==References==
{{Reflist}}

{{PAF signaling}}
{{Benzodiazepines}}

[[Category:Thienotriazolodiazepines]]


{{drug-stub}}